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Brain aging is marked by structural, chemical, and genetic changes leading to cognitive
decline and impaired neural functioning. Further, aging itself is also a risk factor for a
number of neurodegenerative disorders, most notably Alzheimer’s disease (AD). Many
of the pathological changes associated with aging and aging-related disorders have been
attributed in part to increased and unregulated production of reactive oxygen species (ROS)
in the brain. ROS are produced as a physiological byproduct of various cellular processes,
and are normally detoxified by enzymes and antioxidants to help maintain neuronal
homeostasis. However, cellular injury can cause excessive ROS production, triggering a
state of oxidative stress that can lead to neuronal cell death. ROS and intracellular zinc are
intimately related, as ROS production can lead to oxidation of proteins that normally bind
the metal, thereby causing the liberation of zinc in cytoplasmic compartments. Similarly,
not only can zinc impair mitochondrial function, leading to excess ROS production, but
it can also activate a variety of extra-mitochondrial ROS-generating signaling cascades.
As such, numerous accounts of oxidative neuronal injury by ROS-producing sources
appear to also require zinc. We suggest that zinc deregulation is a common, perhaps
ubiquitous component of injurious oxidative processes in neurons. This review summarizes
current findings on zinc dyshomeostasis-driven signaling cascades in oxidative stress and
age-related neurodegeneration, with a focus on AD, in order to highlight the critical role of
the intracellular liberation of the metal during oxidative neuronal injury.
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ROLE OF OXIDATIVE STRESS IN AGING
Brain aging is marked by gradual, general cellular dysfunction
occurring as a result of structural, chemical, and genetic alter-
ations that manifest themselves as cognitive decline, albeit with
great variability among individuals. While these changes are a
normal and unavoidable part of the life cycle of neurons, aging
itself is also a risk factor for a number of late-life neurodegen-
erative disorders including Alzheimer’s disease (AD), Parkinson’s
disease (PD), and amyotrophic lateral sclerosis (ALS). Although
the molecular underpinnings of age-related neuropathology have
not been completely resolved, one recurring explanation for the
alterations observed with age, which has been revisited repeatedly
for nearly 50 years, is the free radical theory of aging. This
theory posits that the deleterious cellular changes that occur
during aging and cognitive decline can be attributed in part to
a continuous deregulation of intracellular reactive oxygen species
(ROS) production over time (Harman, 1965), a phenomenon
usually referred to as oxidative stress. Although this theory has
been modified slightly in more recent years (Beckman and Ames,
1998), oxidative modifications caused by chronic ROS produc-
tion remain recognized as a critical constituent of numerous
neuropathological processes, and therefore represent a vitally
important topic in the field of neurodegeneration research.
In the brain, ROS are produced as a physiological consequence
of the normal oxidative processes related to cellular signaling,
metabolism, and homeostasis (Lander, 1997; D’Autreaux and
Toledano, 2007). Further, in addition to their presence merely
as a passive byproduct of these processes, ROS also play an
important and active role in a number of physiological cellular
functions including gene expression, long-term potentiation, and
the immune response (e.g., Sen and Packer, 1996; Knapp and
Klann, 2002). As such, ROS are an integral component of a
neuron’s intracellular milieu. However, while ROS are important
for normal cellular processing under certain circumstances, they
are more widely recognized for their deleterious role in the initi-
ation and propagation of neuronal injury (Di Carlo et al., 2012;
Lizama-Manibusan and McLaughlin, 2013). Namely, unregu-
lated, excess production of these reactive intermediates during
oxidative stress can have strong toxic effects on proteins, lipids,
and nucleic acids. Moreover, ROS are also capable of triggering
injurious signaling cascades that ultimately result in the demise
of neurons by apoptosis or other forms of cell death (Beckman
and Crow, 1993). Oxidative stress-induced cellular dysfunction
can also exacerbate ROS production downstream of the initial
insult, thereby maintaining the oxidative stress state in a self-
propagating injury cycle that can lead to neuronal death if left
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unchecked (Beckman and Ames, 1998; Finkel and Holbrook,
2000).
ROS GENERATION AND MAINTENANCE OF PROPER
OXIDATIVE HOMEOSTASIS
Under normal circumstances, ROS are produced primarily as
a limited byproduct of oxidative phosphorylation during the
formation of ATP, which occurs via a set of redox reactions in
mitochondria (Chance et al., 1979). Mitochondrial dysfunction,
however, is commonly associated with neural injury cascades,
and thus, in addition to their role in physiological ROS gener-
ation, mitochondria are regarded as one of principal producers
of oxidative intermediates in pathological conditions. ROS them-
selves can also contribute to mitochondrial dysfunction either
indirectly through the initiation of toxic signaling cascades that
target mitochondria, or through direct damage to mitochon-
drial DNA (Richter et al., 1988; Esposito et al., 1999; Melov
et al., 1999; Wallace, 2005). In addition to mitochondria, other
intracellular generators of reactive metabolites also contribute to
oxidative stress during aging, including NADPH oxidases, nitric
oxide synthases (NOSs), lipoxygenases (LOXs), and peroxisomes
(Halliwell and Gutteridge, 2007). Extraneuronal sources of ROS
such as microglia, a non-neuronal, supporting cell involved in
CNS immune responses, as well as exogenous stimuli such as
UV light, ionizing radiation, and environmental toxins, also con-
tribute to age-related neuronal dysfunction.
The brain, despite representing only 2% of the body weight,
receives 15% of the cardiac blood output and accounts for 20%
of the body’s total oxygen consumption (Lassen, 1959). The
pronounced oxidative metabolism present in the brain results
in a large generation of ROS during normal function. Neurons
contain a system of enzymes and antioxidants to detoxify ROS
after they are produced, as well as mechanisms to repair oxidant-
induced damage once it has occurred; still, neurons become
highly vulnerable to ROS-mediated damage when they are not
able to adapt to ROS overproduction during times of stress
(Lizama-Manibusan and McLaughlin, 2013). Therefore, oxidative
stress occurs either from an overproduction of ROS, a deficiency
in the antioxidant response, or both. Oxidative stress can thus
be further defined as a condition in which the number of ROS
produced surpasses a threshold over which they can no longer be
adequately neutralized (Halliwell, 1992). Further, the deleterious
consequences of oxidative stress tend to be exacerbated in the aged
brain due to the combination of increased oxidant production
(Gabbita et al., 1997), along with decreased ability to detoxify
ROS and repair oxidatively stressed tissue (Barnett and King,
1995).
While it is not entirely surprising that cells become less able
to combat the increased concentrations of injurious oxidative
intermediates as they age, oxidative stress does not occur in
isolation, and thus is not solely responsible for the toxic cellular
processes observed during age-related neuropathology (i.e., Lu
et al., 2014). Of course, many interrelated dysfunctional cellular
processes coincide to lead to the immense cell loss observed
during AD and other age-related neurodegenerative disorders.
One such factor, which appears to be inextricably linked to oxida-
tive stress damage in neurons, is zinc dyshomeostasis. Indeed,
much like uncontrolled ROS production can have profoundly
detrimental effects on neurons during aging, dyshomeostasis of
intracellular zinc is also a crucial determinant of the fate of
neurons in the aged brain.
ZINC IN THE BRAIN
Zinc is a ubiquitous trace element found throughout the body,
including the brain, with particular abundance in the auditory
brainstem, olfactory bulb, amygdala, hippocampus, and cortex
(Frederickson et al., 1988, 2000; Weiss et al., 2000; Sekler et al.,
2002). The cation plays a pivotal role in a multitude of cellular
processes including neurotransmission, enzymatic activity, gene
regulation, and structural maintenance and stabilization of pro-
teins (Vallee and Falchuk, 1993; Choi and Koh, 1998; Frederickson
et al., 2005). Due to its widespread function within neurons,
intracellular zinc concentrations are tightly regulated, as proper
homeostasis of the metal is critical in the maintenance of normal
cellular processing. Indeed, zinc binds with high affinity to a
very large number of proteins: roughly 3000 human genes, or
10% of the genome, have been identified as encoding for zinc-
binding proteins (Andreini et al., 2006). While the majority
(80–90%) of the zinc present in the brain is bound to metal-
binding proteins, the remaining fraction is packaged within
synaptic vesicles of a large sub-population of excitatory neurons
(Cole et al., 1999; Frederickson et al., 2000). This synaptic or
vesicular zinc is released in an activity-dependent manner, and
can modulate the activation of several neurotransmitter receptors,
including NMDA, AMPA, GABAA and glycine receptors (for
review see Smart et al., 2004; Paoletti et al., 2009; Sensi et al.,
2011), as well as voltage-dependent ion channels (e.g., Grauert
et al., 2014). In addition, synaptically released zinc interacts
with a specific postsynaptic zinc-sensing metabotropic receptor
(mZnR/GPR39) to modulate synaptic activity through its effect
both on the outward chloride transporter KCC2, and on the
synthesis of 2-arachidonoylglycerol, an endocannabinoid that
modulates probability of presynaptic neurotransmitter release
(Besser et al., 2009; Chorin et al., 2011; Saadi et al., 2012; Perez-
Rosello et al., 2013).
ZINC TOXICITY
It is well established that zinc exposure is toxic to neurons both
in vitro (Yokoyama et al., 1986; Choi et al., 1988) and in vivo
(Lees et al., 1990; Cuajungco and Lees, 1996). The overall con-
centration of the metal within the brain is ∼150 µM, although
the vast majority of intracellular zinc is normally rendered immo-
bile through buffering by cytosolic metal-binding proteins and
sequestration into organelles (Sensi et al., 2011). However, when
neurons are damaged, as occurs during oxidative stress, bound
intracellular zinc can be released into the cytosol, where it then
triggers a number of detrimental signaling processes including
those that lead to further ROS production, marking the start of
a positive feedback loop involving intracellular zinc release and
ROS generation (Aizenman et al., 2000; Zhang et al., 2004a).
Synaptic zinc is also associated with neuronal dysfunction by
its transfer from over-active presynaptic zinc-containing neurons
to postsynaptic cells via calcium-permeable channels, including,
but not limited to a sub-class of AMPA receptors (Weiss et al.,
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1993; Koh et al., 1996; Sensi et al., 2000). While proper zinc
homeostasis is critical at all stages of life, the delicate balance
required to keep zinc levels in check appears to be particularly
precarious in the aged brain (Frazzini et al., 2006; Sensi et al.,
2008; Cipriano et al., 2009; Takeda and Tamano, 2014). This is
likely due to the fact that, as mentioned earlier, relative ROS
levels increase as we age, and intracellular zinc fluxes appear to
be very susceptible to perturbation by ROS. Indeed, zinc has been
proposed as being a critical link between oxidative stress and
aging (Frazzini et al., 2006). To begin to understand the mutual
regulation between intracellular zinc release and ROS generation,
it is first necessary to review what is currently known about
how zinc is maintained within neurons and, more importantly,
how the metal is liberated from metal-binding proteins during
oxidative injury.
ZINC DYSHOMEOSTASIS AND NEURONAL INJURY
While the largest concentration of zinc in the brain is bound
to intracellular metal-binding proteins, there is a second pool,
localized to synaptic vesicles of glutamatergic neurons, which
constitutes 10–20% of the total concentration of the metal in neu-
rons (Frederickson, 1989). In early studies, it had been thought
that cytoplasmic influx of synaptically released zinc, referred to
as “translocation”, was the primary source of toxic intracellular
zinc increases during neuronal injury. This idea, however, was not
consistent with later studies in mice that lacked the gene encoding
ZnT3, the transporter responsible for loading zinc in synaptic
vesicles (Cole et al., 1999). Despite the fact that these animals were
devoid of vesicular zinc, increased intracellular concentrations of
the metal and subsequent cell death still occurred, even in the
apparent absence of zinc translocation from pre- to post-synaptic
neurons (Lee et al., 2000). Thus, these findings strongly suggested
that other sources of zinc release could also be contributing to
the increased intracellular levels of the metal observed during
neuronal injury. Since then, it has become increasingly clear that
increased cytosolic zinc resulting from liberation from intracellu-
lar stores can be highly toxic during oxidative and other types of
neuronal injury.
INTRACELLULAR SOURCES OF ZINC RELEASE
One of the main intracellular zinc binding proteins within neu-
rons is metallothionein III (MT III). MT III is one member of
a family of thiol-rich metal-binding proteins, and is the primary
isoform found in neurons (Hidalgo et al., 2001). Close to a third of
the 61–68 amino acids that constitute MT III are cysteine residues,
cumulatively capable of binding up to seven zinc ions via their
thiol side chains (Vašák and Meloni, 2011). Other MT isoforms
have been shown to bind the seven zinc ions with varying affini-
ties, supporting a role for MTs in the dynamic regulation of zinc
levels dictated by the needs of the cell at any given time (Krezel
and Maret, 2007). In this capacity, MT III acts as an intracellular
regulator of zinc homeostasis via coordinated binding and release
of the metal. Due to the very low redox potential of its thiols
(−366 mV), MT III is readily oxidized, even by relatively mild
oxidants. This oxidation results in the liberation of the bound
zinc ions (Maret and Vallee, 1998); thus, while zinc itself is redox-
inactive, its association with MT III makes it extremely susceptible
to changes in cellular redox state. The release of zinc from MT
III by oxidants causes a substantial increase in intracellular zinc
concentration, and this single event has been established as a
powerful inducer of neuronal injury (Aizenman et al., 2000).
Once zinc is liberated from MT III, it can have numerous
adverse effects on neuronal function (Aras and Aizenman, 2011).
As mentioned previously, mitochondria are the primary produc-
ers of ROS in neurons, and zinc plays a critical role in the regu-
lation of mitochondrial dysfunction and ROS generation during
neuronal injury. Following intracellular liberation of the cation,
mitochondria have been shown to take up cytoplasmic free zinc
through both the calcium uniporter as well as through an inde-
pendent import mechanism that has yet to be identified (Sensi
et al., 2003; Malaiyandi et al., 2005). Once sequestered in the
organelle, zinc can inhibit the electron transport chain, thereby
reducing mitochondrial membrane potential, which subsequently
leads to an increase in ROS generation (Sensi et al., 1999; Dineley
et al., 2005; Dietz et al., 2008; Medvedeva et al., 2009). Interest-
ingly, MT III has also been shown to translocate to mitochondria
and release zinc ions within the mitochondrial intramembranous
space, suggesting a dynamic regulation of zinc homeostasis by the
combined actions of MT III and mitochondria (Ye et al., 2001). In
addition to the MT III-mediated zinc effects on mitochondria, the
organelle itself has been shown to contain an independent store
of zinc, which can be released during injury (Sensi et al., 2003). In
that study, the authors observed that co-treatment with the thiol
oxidant 2,2′-dithiodipyridine (DTDP) and the mitochondrial
protonophore carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP) results in a greater increase in cytosolic
zinc than is observed by treatment with either drug alone, which
the authors attribute to the existence of distinct stores of the
metal that can each be liberated by unique injurious stimuli.
Thus, it appears that mitochondria and MT III work in tandem
to dynamically regulate intracellular availability of the cation.
However, while it is known that both MT III and mitochondria
can modulate zinc levels, additional work is still needed to reveal
the specific contributions of each pool to the propagation of
pro-death cascades following various forms of neuronal injury.
ZINC-MEDIATED ROS GENERATION IN VITRO
In addition to triggering ROS production from mitochondria,
zinc has also been found to be involved in injurious oxidant
generation from a number of extra-mitochondrial sources. Inter-
estingly, ROS generation and intracellular zinc release appear to
be common constituents of a number of toxic signaling pathways
in neurons. One of the better-studied zinc-mediated apoptosis
cascades involves exogenous ROS-triggered zinc liberation and
subsequent generation of endogenous oxidative intermediates.
Specifically, cytosolic accumulation of MT III-liberated zinc can
be caused by exposure to the oxidant DTDP or peroxynitrite
(ONOO−), a physiological oxidant generated by the reaction
between free radicals nitric oxide (NO) and superoxide (Beckman
et al., 1990). The increase in intracellular zinc then promotes
production of superoxide from the enzyme 12-lipoxygenase (12-
LOX), loss of mitochondrial membrane potential, and activation
of Src kinase and p38 MAPK, the latter by upstream MAP kinase
kinase kinase (MAPKKK) apoptosis signal-regulating kinase 1
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(ASK-1; Aizenman et al., 2000; McLaughlin et al., 2001; Zhang
et al., 2004a; Aras and Aizenman, 2005). Once activated, Src
and p38 directly phosphorylate the voltage-gated, delayed rec-
tifier Kv2.1 channel at cytoplasmic residues Y124 and S800,
respectively, to trigger the insertion of new channels into the
plasma membrane, leading to enhanced K+ efflux and con-
sequent reduction in intracellular K+, caspase activation, and
finally, apoptotic cell death (Aizenman et al., 2000; McLaughlin
et al., 2001; Redman et al., 2007, 2009). The oxidant-induced,
zinc-initiated signaling cascade is accompanied by concomitant
intracellular calcium release from the endoplasmic reticulum
(ER), and downstream CaMKII activation, which is necessary for
the exocytotic introduction of Kv2.1 channels into the plasma
membrane (Figure 1; McCord and Aizenman, 2013). Exposure to
NO or activated microglia-derived ONOO− can also initiate this
zinc- and Kv2.1-dependent apoptosis cascade (Bossy-Wetzel et al.,
2004; Knoch et al., 2008), and NO exposure has also been shown
FIGURE 1 | Oxidative injury causes zinc- and calcium-dependent
neuronal apoptosis. An oxidative insult such as DTDP or ONOO−
exposure triggers calcium release from the ER, liberation of zinc from MT III
and mitochondria, and mitochondrial ROS production. Zinc-dependent
12-LOX activation also generates ROS, which feedback on MT III to release
additional zinc. Further, zinc triggers the activation of Src kinase and p38
MAPK (via upstream MAPKKK ASK-1), which then directly phosphorylate
Kv2.1 channels at two amino acid residues, Y124 and S800.
Calcium-activated CaMKII interacts with syntaxin to facilitate the insertion
of phosphorylated Kv2.1 channels into the plasma membrane, causing the
enhancement of K+ currents that is required for apoptosis.
to lead to cytosolic zinc accumulation in hippocampal neurons in
vivo (Cuajungco and Lees, 1998).
Independently, NO, in combination with depletion of the
antioxidant glutathione, was shown to activate 12-LOX, which
results in cell death of neuronal cultures (Canals et al., 2003).
While this study did not investigate the role of intracellular zinc
release in this process, based on the injurious stimulus used
and the downstream effects observed, these findings lend further
support to the notion that various stimuli could trigger a common
zinc-mediated injury cascade. Additionally, a number of studies
have reported cell death following zinc-dependent activation of
NADPH oxidase and nitric oxide synthase (NOS), which are
the enzymes responsible for generating superoxide and NO,
respectively (Halliwell and Gutteridge, 2007). While these reports
focused on the effect of exogenous zinc exposure, considering the
close relationship between intracellular zinc release and ONOO−,
as well the ability of exogenously applied zinc to enter neurons,
it is not unreasonable to assume that intracellular zinc stores may
also play a role in NADPH oxidase and NOS co-activation (Noh
and Koh, 2000; Kim and Koh, 2002). Taken together, it appears
that many of the components involved in injurious mitochondrial
and extra-mitochondrial ROS production, as well as the down-
stream processes triggered by ROS, all seem to share a common
association with intracellular zinc release.
ZINC IN AD
The experimental findings summarized thus far illustrate the
concept that intracellular zinc release is a common toxic event in
certain forms of oxidant-induced neuronal apoptosis. As oxida-
tive stress is a major contributor to brain aging and age-related
pathology, it is feasible that zinc dyshomeostasis may also be
involved in disorders associated with aging neurons (Mocchegiani
et al., 2005). While the exact role of intracellular zinc in the
pathophysiology of neurodegenerative disorders is not entirely
clear, there is a growing body of work implicating the metal
in age-related neurodegeneration. Oxidative stress-induced cell
death is common between AD, PD, and ALS, as well as many
other neurological disorders (Dexter et al., 1989; Olanow, 1993;
Behl et al., 1994; Mecocci et al., 1994; Wiedau-Pazos et al., 1996;
Smith et al., 1998). However, because the literature on the role
of metals in AD is extensive, this review will focus only on zinc
deregulation during AD in an attempt to paint a more cohesive
picture demonstrating the fact that this metal, when unregulated,
can wreak havoc on the health of neurons in an aging brain.
AD is characterized by several pathological hallmarks includ-
ing amyloid plaque deposits, aggregation of neurofibrillary
tangles (NFTs) composed of the protein tau in a hyperphos-
phorylated form, and synaptic loss and neuronal deterioration,
predominantly through apoptosis (Hanger et al., 2009). Amyloid
plaques are comprised primarily of β amyloid (Aβ), a∼40 amino
acid long peptide generated through cleavage of the amyloid
precursor protein (APP; Kang et al., 1987). Accumulation of Aβ
during AD has been shown to cause neuronal apoptosis both in
vitro and in vivo (Kowall et al., 1992; Loo et al., 1993). Addition-
ally, AD and oxidative stress appear to go hand in hand, with ROS
production being both a cause and consequence of Aβ aggregation
(Markesbery, 1997; Butterfield et al., 2001).
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AD-INDUCED CHANGES IN CEREBRAL ZINC
The toxic role of zinc dyshomeostasis has become an important
topic in the study of AD pathology (Bush and Tanzi, 2008;
Greenough et al., 2013). However, the majority of this work has
focused on how synaptically released zinc contributes to AD-
related neuronal dysfunction and death, and studies to char-
acterize the effects of changes in endogenous intracellular zinc
levels remain sparse. Still, the small number of reports that have
examined this source of zinc support a toxic role for increased
intraneuronal zinc in AD. One of the first studies to consider
intracellular zinc deregulation in AD brains found that not only
does the metal localize to extracellular amyloid plaque deposits,
but that cytosolic zinc levels are increased as well, particularly
in neurons exhibiting intracellular NFTs (Suh et al., 2000). More
recently, the effect of oxidative stress on intracellular zinc mobi-
lization was determined in neurons derived from 3xTg-AD mice,
a triple transgenic AD mouse model that exhibits both Aβ and tau
pathology. Importantly, this study found that intracellular zinc
levels are substantially higher in 3xTg-AD neurons than in control
cells following exposure to DTDP (Sensi et al., 2008). Thus, while
studies of cytosolic zinc changes in AD are still in their relative
infancy, these results suggest that intracellular zinc liberation
could be critical for the progression of AD pathology, and that
these effects appear to be mediated by the metal’s interaction with
ROS.
ZINC-MEDIATED β AMYLOID AGGREGATION AND TAU
PHOSPHORYLATION
Zinc plays an important role in Aβ aggregation, as the peptide
has been shown to bind to the metal (Bush et al., 1994a).
Additionally, not only does zinc exposure induce the aggregation
of amyloid plaques (Bush et al., 1994b; Esler et al., 1996), but
the plaques themselves are also rich in zinc, as well as copper.
It is thought that Aβ is primarily responsible for inducing a
state of oxidative stress during AD through direct production
of oxidants (Markesbery, 1997; Huang et al., 1999; Butterfield
et al., 2001), as well as through activation of microglia and
subsequent generation of ONOO− (Goodwin et al., 1995; Meda
et al., 1995; McDonald et al., 1997; Sturchler-Pierrat et al., 1997;
Weldon et al., 1998). As mentioned earlier, ONOO− production
originating from both neurons and microglia appears to be a
key trigger of zinc-dependent neuronal apoptosis (Zhang et al.,
2004a; Knoch et al., 2008). Further, hydrogen peroxide, an oxidant
produced by Aβ directly (Huang et al., 1999), can cause the release
of zinc from MT III, subsequently causing aggregation of Aβ.
Although it was not specified if MT III is localized intra- or
extracellularly, Aβ aggregates induced by endogenous zinc release
are morphologically distinct from those induced by exogenous
zinc application, suggesting a unique role for different zinc pools
during AD (Durand et al., 2010). Interestingly, chelation of the
cation facilitates the dissolution of these toxic deposits both in
vitro (Huang et al., 1997) and in post-mortem AD brain tissue
(Cherny et al., 1999). Unlike humans, aged mice and rats do not
express Aβ in an aggregated form, and as such, do not exhibit
the related neuropathology. Intriguingly, one notable difference
between human and rodent Aβ is the peptide’s ability to bind
zinc, with human Aβ exhibiting a much higher affinity for the
metal (Huang et al., 2004). Thus, it is tempting to speculate
that zinc could be directly responsible for the characteristic toxic
aggregation of Aβ observed in AD patients, although more work
is needed to definitively confirm this.
While it is known that both exogenous and synaptically
released zinc induce Aβ aggregation (Bush et al., 1994b;
Deshpande et al., 2009), it appears that increased intracellular zinc
may also play a role in this process, although conclusive work
demonstrating this has yet to be undertaken. Aβ was originally
identified as solely localizing extracellularly; however, other stud-
ies have shown that Aβ is also found in the cytoplasm of neurons
(Turner et al., 1996; Wild-Bode et al., 1997; Gouras et al., 2000).
Interestingly, a number of studies have shown that intracellular
Aβ (Aβi) formation precedes the appearance of extracellular Aβ,
lending support to the hypothesis that an intracellular pool of the
peptide is a prerequisite for extracellular plaque formation (Walsh
et al., 2000; Wirths et al., 2001). However, further work is required
to clarify if Aβi plays a causative role in the formation of extracel-
lular plaques, and if intracellular zinc release promotes the induc-
tion of Aβi. Nonetheless, in support of a role for cytosolic zinc,
Aβi accumulation has been shown to correlate with microglial
activation, increased NO production, and p38 activation (Rodrigo
et al., 2004; Takuma et al., 2009), all of which are events that have
previously been linked to pro-apoptotic intracellular zinc release
(McLaughlin et al., 2001; Bossy-Wetzel et al., 2004; Knoch et al.,
2008). Further, Aβi accumulation can be triggered by exposure
to oxidants (Ohyagi et al., 2000), and its accumulation has been
shown to be localized to mitochondria, which also contain zinc
(Rodrigo et al., 2004), and to the ER (Hartmann et al., 1997),
an organelle recently shown to be involved in zinc- and Kv2.1-
dependent neuronal apoptosis (McCord and Aizenman, 2013).
Zinc has been shown to be localized to the ER (Stork and Li,
2010; Taylor et al., 2012), and is released following OONO−
exposure (Lin et al., 2013), further bolstering a potential role for
the cation in Aβi accumulation within the ER. Taken together, it
is reasonable to hypothesize that intracellular zinc release could
be an important factor in the accumulation of Aβ within neurons
observed during AD (Figure 2).
Despite the presence of zinc in Aβ and evidence for its critical
role in the aggregation of this toxic peptide, not all findings
support a deleterious role for zinc in AD. In fact, exposure to
low micromolar concentrations of the metal has been shown to
destabilize Aβ aggregation and be protective against Aβ-induced
toxicity (Garai et al., 2007). However, while low levels of zinc may
protect neurons from Aβ-mediated damage, exposure to higher
concentrations of the metal are toxic under otherwise equivalent
conditions (Lovell et al., 1999). Like the effect of exogenous zinc
on AD-related toxicity, the concentration of endogenous zinc
within AD brains is also a contentious issue, although discrepan-
cies in these studies could very well be a result of differences in the
conditions under which the measurements were taken. Nonethe-
less, it appears that although some studies report decreased zinc
levels in certain regions of AD brains (Danscher et al., 1997;
Panayi et al., 2002), the overall trend supports an increase in
cerebral zinc during AD (Thompson et al., 1988; Deibel et al.,
1996; Danscher et al., 1997; Religa et al., 2006). Indeed, zinc
chelation has proven to be neuroprotective against Aβ-mediated
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FIGURE 2 | Both extra- and intracellular zinc contribute to the toxic
aggregation of Aβ during AD. Synaptically released zinc, following secretion
of zinc-containing glutamatergic vesicles, facilitates Aβ aggregation after the
peptide has been cleaved from membrane-bound APP. An increase in
intracellular zinc, which can be liberated from numerous sources, also
enhances Aβ accumulation in the cytosol of neurons. Further, both Aβ
aggregates and zinc have been found within mitochondria, lysosomes, and
the ER.
toxicity (Lee et al., 2004). Moreover, high concentrations of
the metal have been localized to amyloid plaques and neuropil
derived from AD brains (Constantinidis, 1990; Lovell et al., 1998;
Suh et al., 2000), further supporting a role for increased zinc in
brain areas relevant to AD pathology. Aβ-localized zinc has also
been shown to contribute to AD-related damage via its effect on
toxic iron accumulation (Duce et al., 2010). During AD, increases
in intracellular iron can exacerbate oxidative stress and contribute
to tau aggregation (Bartzokis et al., 1994; Smith et al., 1997;
Yamamoto et al., 2002). Recently, APP was shown to possess
ferroxidase activity that contributes to iron export and a reduction
in oxidative stress in a mouse model of AD. APP ferroxidase
activity is inhibited by zinc, and is negatively correlated with
increased Aβ accumulation, suggesting that the zinc originated
from within amyloid plaques (Duce et al., 2010). Aβ pathology
can also influence the activity of certain kinases that have been
closely associated with zinc deregulation and neuronal injury.
Namely, numerous studies report increased phosphorylation of
p38 in AD brains (Hensley et al., 1999; Zhu et al., 2000, 2001;
Pei et al., 2001; Sun et al., 2003), which is also required for zinc-
mediated neuronal apoptosis (McLaughlin et al., 2001). Addi-
tionally, ASK-1, the upstream MAPKKK of p38, has been linked
to AD-related toxicity. Specifically, Aβ-mediated ROS production
leads to activation of ASK-1 and downstream cell death in PC12
cells and cortical neurons (Kadowaki et al., 2005). Thus, many of
the pathological changes that take place during AD appear to be
very similar to those observed in injury related to oxidant-induced
zinc liberation and downstream apoptosis.
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Similar to Aβ, zinc can also directly bind to tau to facilitate
aggregation of the protein into NFTs (Mo et al., 2009). Like the
bimodal regulation of Aβ-induced toxicity, modulation of tau by
exogenous zinc also appears to be concentration-dependent, with
lower concentrations of the metal causing a decrease in phospho-
tau, while higher levels cause an increase (Boom et al., 2009).
Although these findings are based on exogenously applied zinc,
the authors conclude that because tau accumulates intracellularly,
the observed effect is likely due to translocation of exogenous zinc
into the cytosol. Thus, while the effect of endogenous intracel-
lular zinc release was not investigated, these studies nonetheless
support a potential role for intracellular liberation of the cation
in the regulation of tau during AD. Further support for this
idea comes from evidence for accumulation of zinc predomi-
nantly within neurons that display NFTs (Suh et al., 2000). As
mentioned previously, hyperphosphorylation of tau is required
for its aggregation into NFTs, and many of the kinases involved
in the zinc- and Kv2.1-mediated apoptosis cascade described
previously also phosphorylate tau. Specifically, tau can be directly
phosphorylated by both p38 (Reynolds et al., 1997) and CaMKII
(Litersky et al., 1996). Further, exogenous zinc application can
trigger Src kinase-dependent inactivation of PP2A, the primary
phosphatase responsible for dephosphorylating tau (Liu et al.,
2005, 2008). As mentioned earlier, zinc-dependent Src activity
is also responsible for phosphorylating Kv2.1 channels prior to
their insertion into the plasma membrane during to apoptosis
(Redman et al., 2009).
EFFECT OF ZINC ON AUTOPHAGIC DYSFUNCTION
DURING AD
Autophagy is a catabolic system used within cells to clear dys-
functional or unused proteins and macromolecules before they
cause damage to neurons. Degradation of malfunctioning cel-
lular components during autophagy occurs in lysosomes, which
are acidic organelles containing hydrolase enzymes that facili-
tate the decomposition process. Autophagy is important in the
clearance of protein aggregates (Johansen and Lamark, 2011),
and autophagic deregulation has come to be regarded as a key
occurrence in AD-related pathology (Cuervo, 2008; Nixon and
Yang, 2011). It has been suggested that cell death can result from
oxidative stress-induced accumulation of Aβ within lysosomes,
leading to lysosomal membrane permeabilization (LMP) and
subsequent release of Aβ and other toxic molecules into the
cytosol (Zheng et al., 2009). In addition to toxicity caused by
LMP, reduced autophagy, which has been observed in AD, can
also lead to cell death due to a buildup of damaged molecules
that would otherwise be degraded. In this scenario, decreased
autophagy can be toxic to neurons independently of the effects
of LMP. While this area of AD research is still relatively new, zinc
also appears to play an important role in lysosomal dysfunction
triggered by oxidative stress. Namely, oxidant exposure has been
shown to cause an accumulation of zinc within lysosome-derived
vesicles, as well as within the cytosol itself, leading to apoptosis of
hippocampal neurons. Further, apoptosis is prevented by the zinc
chelator TPEN, demonstrating that the increase in cytosolic zinc
is responsible for the observed toxicity (Hwang et al., 2008).
Zinc deregulation during autophagic dysfunction has also
been shown to have clinical significance. Administration of the
prototype AD drug clioquinol can cause a reduction of tau and
Aβ, as well as an improvement in cognitive performance (Regland
et al., 2001; Ritchie et al., 2003). The effect of clioquinol on Aβ
aggregation was initially thought to occur because of the drug’s
ability to chelate zinc (Cherny et al., 2001). However, more recent
work revealed that clioquinol actually functions by acting as an
ionophore-like compound to increase influx of zinc into cells
from the extracellular space, which can then induce autophagy in
neurons and astrocytes (Park et al., 2011). Specifically, this study
found that zinc localizes to autophagic machinery (autophagic
vacuoles, autolysosomes, and lysosomes), and is necessary for
the clioquinol-induced clearance of accumulated huntingtin pro-
tein, which aggregates in Huntington’s disease. Thus, it appears
that clioquinol may be important in degrading the Aβ and
tau aggregates observed in AD, in part through its effect on
extra- and intracellular zinc levels (Figure 3). However, this
same study also showed that clioquinol causes zinc-dependent
cell death in cortical neurons, although this experiment was
not performed in the presence of Aβ or under other conditions
that would mimic zinc levels or the overall cellular environment
manifested in AD, and it is thus difficult to deduce the effect
of clioquinol on neuronal viability during AD from this study
alone.
Both abnormally increased and decreased autophagy can be
detrimental to neurons depending on the circumstances in which
it takes place. The studies summarized here underscore the com-
plex nature of the role of zinc in regulating autophagic dysfunc-
tion. Indeed, it appears that changes in intracellular zinc levels
can dictate if autophagy will adopt a pro-death or pro-survival
function (Lee and Koh, 2010). As zinc dyshomeostasis can be
observed both extracellularly and intracellularly during AD, much
work remains to acquire a better understanding of the delicate bal-
ance of zinc that underlies normal cellular function, and at exactly
what point metal-regulatory processes go awry to propagate the
pathological effects observed during neurodegeneration.
MT III AND AD
As mentioned previously, MT III is one of the primary zinc-
binding proteins within neurons, and therefore plays an integral
role in maintaining homeostasis of the metal. In contrast to MT I
and MT II, which are normally induced by increased levels of free
metals within cells, MT III is constitutively expressed. Knockdown
of MT III can lead to increased oxidant-triggered intracellular zinc
levels, while overexpression of the protein substantially reduces
the amount of zinc detected within neurons following oxidant
exposure (Aras et al., 2009). Interestingly, numerous indepen-
dent studies have reported downregulation of MT III during
AD (Uchida et al., 1991; Tsuji et al., 1992; Yu et al., 2001).
While these studies did not directly measure the effect of reduced
MT III expression on intracellular zinc levels, they suggest that
increased intracellular zinc concentration due to a reduction in
MT III expression could be relevant to the pathological effects
observed during the progression of the disease. Others, looking
at the molecular consequences of changes in MT III during
AD have shown that exogenous MT III exposure prevents the
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FIGURE 3 | Complex regulation of lysosomal function and autophagy
by zinc. (Left panel) Oxidative injury can lead to accumulation of zinc and
Aβ within lysosomes, presumably following zinc liberation from internal
stores such as MT III. This accumulation triggers LMP, which causes cell
death due to the release of zinc, Aβ, and other toxic molecules like
hydrolases into the cytosol. Alternatively, under other conditions zinc may
have a protective effect by restoring autophagy, which is reduced in AD.
(Right panel) Clioquinol, a clinically effective AD drug, increases
intracellular zinc concentration by acting as an ionophore-like compound for
the cation. Zinc accumulates in autophagic vesicles, which is necessary for
the induction of autophagy and clearance of protein aggregates. However,
while clioquinol has been shown to cause a reduction in Aβ and an
improvement in cognitive performance in clinical trials, it can also cause
zinc-mediated toxicity in otherwise healthy neurons in vitro, demonstrating
the need for future work to clarify the role of zinc in AD-related autophagic
dysfunction.
accumulation of Aβ and rescues neurons from Aβ-induced cell
death (Irie and Keung, 2001), supporting a beneficial role of
MT III through the sequestration of extracellular zinc. Along
these lines, MT III has been suggested to be secreted by cells
in the brain, albeit by not well-defined pathways (Chung and
West, 2004; Manso et al., 2011). Seemingly paradoxically, a small
number of studies have reported increased MT III expression in
AD (Zambenedetti et al., 1998; Carrasco et al., 1999), although
investigations describing this phenomenon are much less com-
mon than those reporting decreased MT III. Further, MT III can
act as both an acceptor and a donor of zinc, and thus changes in
MT III expression could have different effects depending on the
cellular environment and redox state within neurons. Knockdown
of MT III in astrocytes has also been shown to lead to a decrease
in the degradative capacity of lysosomes (Lee et al., 2010), consis-
tent with the reduced autophagy observed during AD. However,
the lack of MT III also corresponds with decreased oxidant-
induced zinc release, revealing the need for further studies to
fully understand the role of MT III and its association with zinc
in autophagic dysfunction. Nonetheless, the fact that changes in
MT III expression are almost universally observed in AD suggests
that deregulation of MT III is likely contributing to the zinc
dyshomeostasis observed.
ZINC AND ITS RELATION TO CALCIUM DEREGULATION
DURING AD
Like zinc, intracellular calcium dyshomeostasis also appears to
play a crucial role in AD-related pathology (LaFerla, 2002;
Berridge, 2010, 2013). Simultaneous increases in intracellular
zinc and calcium have been observed in a number of injurious
signaling cascades related to ischemic, excitotoxic, and oxidative
injury (Sensi et al., 2002; Medvedeva et al., 2009; Vander Jagt
et al., 2009). However, details regarding the downstream signaling
pathways activated by these two metals during oxidative injury
are just beginning to arise (McCord and Aizenman, 2013). Sim-
ilarly, although evidence has implicated calcium dyshomeostasis
Frontiers in Aging Neuroscience www.frontiersin.org April 2014 | Volume 6 | Article 77 | 8
McCord and Aizenman Oxidant-induced zinc liberation
as a trigger for AD pathology (Khachaturian, 1989), if and how
calcium and zinc cooperate to regulate pathological signaling
during AD is still unclear. While there is some indication of a
correlation between intracellular zinc and calcium levels in AD
brains (Ishihara et al., 2002), direct evidence linking the two
metals to pathological processes specifically associated with this
disorder does not yet exist. Still, despite the lack of definitive
proof, intracellular calcium and zinc release do appear to mediate
many of the same processes during AD.
Just as Aβ can induce zinc liberation from internal, metal-
binding stores via ROS production, the peptide can also trigger
calcium release from the ER. This increase in calcium leads to ROS
generation, mitochondrial dysfunction, caspase activation, and
apoptosis (Ferreiro et al., 2006). As discussed earlier, all of these
cellular changes have also been reported during oxidant-induced,
zinc- and calcium-mediated neuronal apoptosis. Additionally, like
zinc, cellular alterations induced by increased intracellular cal-
cium contribute to intraneuronal Aβ accumulation and neurotox-
icity (Pierrot et al., 2006; Demuro and Parker, 2013). Specifically,
a depolarization-induced increase in cytosolic calcium can trigger
phosphorylation of APP and tau, leading to subsequent Aβi
accumulation and cell death (Pierrot et al., 2006). These calcium-
dependent phosphorylation events are mediated by GSK-3β, a
kinase known for its role in the phosphorylation of both tau
and APP (Aplin et al., 1996) that has previously been shown to
be activated downstream of ER calcium release (Hartigan and
Johnson, 1999). Zinc can also induce GSK-3β phosphorylation,
an event that corresponds to zinc-mediated activation of p38
MAPK (An et al., 2005). In another study, accumulation of Aβi
was shown to trigger IP3-mediated calcium release from the ER
that is necessary for Aβi-induced toxicity (Demuro and Parker,
2013).
Like zinc, changes in intracellular calcium levels are extremely
sensitive to oxidative stress. DTDP, a common inducer of intracel-
lular zinc release (Aizenman et al., 2000; McLaughlin et al., 2001),
has also been shown to trigger calcium release from the sarcoplas-
mic reticulum following oxidation of ryanodine receptors (RyRs)
in cardiomyocytes (Zaidi et al., 1989). Further, DTDP-induced ER
calcium release has recently been observed during zinc-dependent
apoptosis in cortical neurons (McCord and Aizenman, 2013).
Additionally, RyRs can also be nitrosylated by nitric oxide, lead-
ing to calcium release (Xu et al., 1998; Kakizawa et al., 2013).
Deregulation of both the ER and mitochondria and the resultant
effects on intraneuronal calcium levels appear to be important
determinants of the progression of AD-related pathological pro-
cesses (Green et al., 2008; Adam-Vizi and Starkov, 2010; Mattson,
2010). Both oxidative stress and mitochondrial dysfunction have
been shown to occur early in the pathogenesis of AD (Nunomura
et al., 2001; Moreira et al., 2006), and mitochondria and the ER
can physically interact to regulate intracellular calcium levels in
response to changes in redox state (Csordas and Hajnoczky, 2009;
Hayashi et al., 2009). As mentioned previously, intracellular zinc
can also regulate mitochondria and ROS production (Dineley
et al., 2003; Sensi et al., 2003). Further, increased intracellular
calcium triggered by glutamate exposure has been shown to
contribute to mitochondrial ROS production and subsequent
release of zinc from intracellular stores (Dineley et al., 2008).
While these studies were not specific to any one disease, it is
conceivable that similar injurious parallel processes are taking
place during AD. In fact, a signaling cascade has been proposed
to account for the seemingly coordinated pathways activated by
zinc and calcium during AD (Corona et al., 2011). Taken together,
and considering the interrelated roles of calcium and zinc in
other injury models, work to reveal potential parallel processing
by the metals awaits as an exciting new opportunity to enhance
our understanding of the cellular signaling events underlying AD
neuropathology.
ZINC AND NORMAL BRAIN AGING
Although proper regulation of cytoplasmic zinc is crucial in
determining the fate of neurons during AD and other neu-
ropathological conditions, little is known regarding the status of
intracellular release of the metal during normal, healthy aging. It
is known, however, that the concentration of vesicular zinc, and
the expression of ZnT3, the transporter responsible for packaging
zinc into synaptic vesicles, are reduced with increasing age. Specif-
ically, synaptic zinc levels have been shown to be decreased in the
hippocampus of aged rats (Ricci et al., 1989; Amenta et al., 1990;
Mocchegiani et al., 2004), and this reduction correlates with age-
induced memory impairments (Guidolin et al., 1992). Further,
Adlard et al. (2010) observed age-dependent memory deficits in
mice lacking the gene encoding ZnT3, and also found reduced
cortical ZnT3 levels in aged wild-type mice, as well as in healthy,
older humans between the ages of 48–91 years. Low hippocampal
ZnT3 expression and concomitant decrease in vesicular zinc con-
centration has also been observed in the senescence-accelerated
mouse prone 10 (SAMP10) model of aging (Saito et al., 2000).
While vesicular zinc levels decrease as a function of age, the total
concentration of the metal in the brain appears to be unaffected
by increasing age in both rodents and humans (Takahashi et al.,
2001; Rahil-Khazen et al., 2002).
Though the role of cytoplasmic zinc in normal aging remains
unclear, increased intracellular zinc concentration due to influx of
the metal from extracellular space was recently shown to restore
age-associated cognitive deficits in mice. Namely, administration
of PBT2, a second-generation 8-hydroxy quinolone analog of the
zinc ionophore-like AD drug clioquinol, improves cognitive abil-
ity in aged mice through a mechanism involving redistribution
of zinc, resulting in an overall increase of the metal within hip-
pocampal neurons, as well as concurrent cellular changes indica-
tive of neurogenesis and enhanced synaptic plasticity. The status
of intracellularly stored zinc was not monitored in this study,
although overall brain zinc levels were unchanged by administra-
tion of PBT2 (Adlard et al., 2014). In addition to diminishing cog-
nitive decline during normal aging, PBT2 also improves cognitive
performance in mouse models of AD (Adlard et al., 2008). Thus, it
seems that age-related cognitive impairment could occur through
similar mechanisms under both physiological and pathological
circumstances, and that cerebral zinc dynamics play an important
part of the cellular processes underlying these cognitive changes.
As such, determining how zinc localized to intracellular stores
contributes to the cognitive deficits that accompany aging could
greatly enhance our understanding of the function of the metal
during normal aging.
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Dietary zinc deficiency is common among the elderly, and has
been attributed to dysfunction in the body’s immune response,
including changes in the antioxidant defense system, which
manifest in part as an increase in the incidence of infection and
inflammatory processes (Kelly et al., 1996; Mocchegiani et al.,
2000, 2008; Haase and Rink, 2009; Wong et al., 2013). Unfortu-
nately, although zinc deficiency is frequently observed in the aged
population, results regarding the effect of zinc supplementation
on healthy aging have been somewhat inconsistent, and a con-
sensus has yet to be reached on the benefits of such treatment
(Mocchegiani et al., 2008). Most studies on the effect of zinc
deficiency on aging have been focused on areas of the body
outside of the brain, and thus, at present, the effects of dietary
zinc deficiency on brain aging are not well understood. While
it has been shown that activities of many proteins known to be
modulated by zinc are altered with increasing age, there is a dearth
of reports explicitly studying if and how dietary zinc deficiency
contributes to these changes (for review see Mocchegiani et al.,
2005). As such, additional research is needed to clarify the role of
dietary zinc in the aging brain.
Kv2.1-MEDIATED K+ EFFLUX AND AD
A necessary downstream event in zinc-mediated apoptosis is
enhanced K+ efflux through the delayed-rectifier Kv2.1 channel.
Low intracellular K+ is a requisite step in many apoptosis path-
ways, as it facilitates protease and nuclease activation, cytochrome
c release from mitochondria, and apoptosis-related cellular vol-
ume decrease (Bortner et al., 1997; Hughes et al., 1997; Yu et al.,
1997; Maeno et al., 2000; Cain et al., 2001). Intracellular zinc
release and downstream Kv2.1-mediated K+ efflux can both be
triggered by exposure to DTDP, NO, and activated microglia
(Pal et al., 2003; Bossy-Wetzel et al., 2004; Knoch et al., 2008).
Further, oxidant-induced K+ current enhancement is prevented
by the zinc chelator TPEN, demonstrating the dependence of
apoptotic Kv2.1 activity on zinc (McLaughlin et al., 2001). In
addition to its role in zinc-mediated apoptosis, Kv2.1 also appears
to be involved in the toxic cellular processes related to AD. For a
number of years, studies have demonstrated an enhancement of
voltage-gated, delayed rectifier K+ currents following exposure of
neurons and astrocytes to Aβ (Jalonen et al., 1997; Colom et al.,
1998; Yu et al., 1998). More recently, though, changes specifically
within the Kv2.1 channel have been identified in animal models
of AD. Namely, upregulation of Kv2.1 mRNA and protein has
been reported in rats injected with Aβ; this change in Kv2.1
expression is accompanied by impaired performance on spatial
memory tasks (Pan et al., 2004). It is well known that deficits
in acetylcholine are intimately related to AD-associated cognitive
decline, thus forming the basis of acetylcholinesterase (AChE)-
based therapy in the disease (Bartus et al., 1982; Francis et al.,
1999). Interestingly, the AChE inhibitor galantamine, used in the
treatment of AD, has been shown to cause a reduction in basal
delayed rectifier K+ currents in hippocampal neurons (Pan et al.,
2003; Vicente et al., 2010), likely arising from Kv2.1 channels
(Zhang et al., 2004b).
Hydrogen peroxide exposure has been shown to directly oxi-
dize Kv2.1 channels, leading to channel oligomerization and
downstream apoptosis. Importantly, an oxidation-resistant Kv2.1
channel cysteine mutant (C73A) that prevents oligomerization
also attenuates toxicity induced by Aβ exposure (Cotella et al.,
2012). Interestingly, enhanced oligomerization of Kv2.1 is also
observed in a mouse model of AD, although how this change
in Kv2.1 structure contributes to AD-related cognition decline
was not determined (Cotella et al., 2012). In contrast to reports
of enhanced Kv2.1-mediated K+ currents during apoptosis, this
study found that oxidant exposure actually decreases K+ currents,
and the Kv2.1C73A mutation blocks this effect. However, this
discrepancy could be explained by the fact that it takes ∼3 h
to observe the Kv2.1-mediated K+ current enhancement after
oxidant exposure (McLaughlin et al., 2001), and this group only
examined currents immediately following the oxidative insult.
Further, the toxic effects of Kv2.1 channel oligomerization may
occur independently of the change in K+ currents, as a second
oligomerization-impaired channel mutant (C73S) was found to
be non-conducting, yet still rescues cells from oxidant-induced
apoptosis (Cotella et al., 2012). Thus, it is not yet clear how
alterations in Kv2.1-mediated K+ currents may influence Aβ-
mediated toxicity.
CONCLUSIONS
Oxidative stress can generally be considered both a cause and an
effect of the neuropathological changes seen in AD and other age-
related neurodegenerative disorders. In addition, links between
increased intracellular zinc, oxidative stress, and age-related neu-
rodegeneration have been established in numerous studies, and
zinc dyshomeostasis appears to be a common constituent of
a multitude of pathological neuronal processes. Nonetheless, a
direct causative role of intracellular zinc release in human neu-
rodegenerative disorders has yet to be firmly established. It is
known that zinc homeostasis is critical for proper brain function,
and even minor disturbances to this delicate balance can trigger an
accumulation of zinc, which can have extremely adverse effects on
the fate of neurons in AD and related disorders, in part through an
apoptotic enhancement of Kv2.1-mediated K+ currents. As such,
modulation of intracellular zinc levels could be a particularly
important target in order to protect against AD-related injurious
cellular processes. However, while chelation of zinc may be an
effective neuroprotective strategy in vitro, the potential therapeu-
tic benefits of zinc chelation become much more complex when
studying changes in zinc levels in vivo, in particular as zinc can
also act as a neuromodulator or neurotransmitter, and it has a
wide range of additional essential functions in neurons, as well as
throughout the organism, including, but not limited to regulation
of gene expression. This matter is thus complicated by the fact that
both increased and decreased intracellular zinc can be neurotoxic,
presumably depending on specific cellular conditions. Still, the
fact that drugs like the zinc ionophore-like compound clioquinol
have been effective in abrogating some of the pathological conse-
quences of AD in preliminary clinical trials (Regland et al., 2001;
Ritchie et al., 2003), presumably through its effect on modulating
zinc levels in order to restore autophagy, indicates that the metal
plays a pivotal role in the progression of AD, and that strategies
targeting zinc could hold the key to finding better treatments for
this currently incurable disease. Still, future work is required to
determine exactly how clioquinol and its association with zinc
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improve the outcome of AD progression. Further, investigation
into the potential off-target effects of this drug is crucial, as
increased intracellular zinc, as illustrated throughout this review,
is lethal to neurons in a variety of settings.
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